Advanced Combination Therapy with Tofacitinib and Biologic Agents for Psoriasis and Psoriatic Arthritis: A Case Series
This case series adds to the sparse data on combining biologics and JAK inhibitors for the treatment of psoriatic disease. Advanced combination therapy with a JAK inhibitor and a targeted biologic agent may represent a relevant treatment option in selected cases of treatment-refractory psoriatic disease. However, larger studies are needed to establish the safety and efficacy of this combination.
Authors
- Trine Bay Laurberg (ORCID: https://orcid.org/0000-0003-3083-0745)
- Cathrine Dawn Büttner Elgaard (ORCID: https://orcid.org/0000-0003-1965-4242)
- Anne Gitte Loft (ORCID: https://orcid.org/0000-0001-6374-841X)
- Jørgen Agnholt (ORCID: https://orcid.org/0000-0003-2822-6442)
- Kasper Fjellhaugen Hjuler (ORCID: https://orcid.org/0000-0001-6082-5096)
Institutions
- Aalborg University Hospital (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- Case Reports in Dermatology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1159/000547724
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00